sábado, 16 de diciembre de 2017

Combined Annotation Dependent Depletion (CADD) Score for BRCA1/2 variants in patients with Breast and/or Ovarian Cancer. - PubMed - NCBI

Combined Annotation Dependent Depletion (CADD) Score for BRCA1/2 variants in patients with Breast and/or Ovarian Cancer. - PubMed - NCBI





 2017 Dec 7. doi: 10.1111/cas.13464. [Epub ahead of print]

Combined Annotation Dependent Depletion (CADD) Score for BRCA1/2 variants in patients with Breast and/or Ovarian Cancer.

Abstract

The utility of Combined Annotation Dependent Depletion (CADD) Score was recently reported to rank the pathogenicity as C-scores ranging 1 to 99 for both convinced deleterious mutations and missense mutations. Using C-scores for BRCA1/2 variants, we tried to constitute the classification system for Variant of Uncertain Significance (VUS), which had been major problem of genetic testing for Hereditary Breast and/or Ovarian Cancer (HBOC). We analyzed BRCA1/2 genes for 283 patients with breast and/or ovarian cancer. The deleterious mutation, minor variant, and wild type of BRCA1 and 2 were 5, 27, 251 and 15, 85, 183, respectively. While, the variants with C-score≧10 were involved 19/283 (6.7%) in BRCA1 and 34/283 (12%) in BRCA2. All deleterious mutations were included in this group. The frequency of personal history and family history of ovarian cancer were significantly high, and frequency of serous adenocarcinoma of ovary and triple negative breast cancer was relatively high in group with deleterious mutations. Similar findings were seen in patients with variants of C-score≧10. According to the C-score and population frequency, we could define VUS for 11 patients out of 283 patients (3.8%). CADD is useful to classify the variant of BRCA1/2 and selecting the patient who needs further segregation studies. This article is protected by copyright. All rights reserved.

KEYWORDS:

BRCA ; Combined Annotation Dependent Depletion (CADD); Hereditary Breast and/or Ovarian Cancer (HBOC); Variants of Uncertain Significance (VUS); and Genetic Counseling

PMID:
 
29215753
 
DOI:
 
10.1111/cas.13464
Free full text

No hay comentarios:

Publicar un comentario